A detailed history of Wolverine Trading, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Wolverine Trading, LLC holds 55,511 shares of VKTX stock, worth $2.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,511
Previous 18,049 207.56%
Holding current value
$2.35 Million
Previous $956,000 267.57%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$49.84 - $70.47 $1.87 Million - $2.64 Million
37,462 Added 207.56%
55,511 $3.51 Million
Q2 2024

Aug 14, 2024

SELL
$47.39 - $80.2 $138,615 - $234,585
-2,925 Reduced 13.95%
18,049 $956,000
Q1 2024

May 15, 2024

BUY
$17.4 - $94.5 $170,311 - $924,966
9,788 Added 87.5%
20,974 $1.72 Million
Q4 2023

Feb 14, 2024

SELL
$9.24 - $19.64 $260,909 - $554,574
-28,237 Reduced 71.63%
11,186 $208,000
Q3 2023

Nov 15, 2023

SELL
$10.92 - $16.0 $1.23 Million - $1.8 Million
-112,383 Reduced 74.03%
39,423 $436,000
Q2 2023

Aug 23, 2023

SELL
$14.84 - $24.79 $184,861 - $308,809
-12,457 Reduced 7.58%
151,806 $2.46 Million
Q1 2023

May 15, 2023

BUY
$8.08 - $17.33 $1.04 Million - $2.22 Million
128,120 Added 354.48%
164,263 $2.85 Million
Q4 2022

Feb 14, 2023

BUY
$2.72 - $9.4 $98,308 - $339,744
36,143 New
36,143 $340,000
Q4 2021

Feb 14, 2022

SELL
$4.6 - $6.72 $66,079 - $96,532
-14,365 Reduced 46.92%
16,250 $75,000
Q1 2020

May 11, 2020

BUY
$3.45 - $7.95 $105,621 - $243,389
30,615 New
30,615 $145,000
Q1 2019

May 15, 2019

SELL
$7.58 - $9.94 $316,646 - $415,233
-41,774 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$7.16 - $16.21 $189,281 - $428,527
-26,436 Reduced 38.76%
41,774 $316,000
Q3 2018

Nov 14, 2018

BUY
$9.7 - $19.65 $661,637 - $1.34 Million
68,210 New
68,210 $1.19 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.